Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2018

Balance Sheet Components

Schedule of cash equivalents and available-for-sale securities

Cash equivalents and available-for-sale securities consisted of the following (in thousands):

	September 30, 2018
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Money market funds	$	27,582	$	—	$	—	$	27,582
Corporate bonds		6,031		—		(11)		6,020
Commercial paper		62,386		—		—		62,386
Government bonds		39,261		—		(69)		39,192
Total cash equivalents and available-for-sale securities	$	135,260	$	—	$	(80)	$	135,180
Classified as:
Cash equivalents							$	84,090
Available-for-sale securities - current								51,090
Total cash equivalents and available-for-sale securities							$	135,180

	December 31, 2017
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Money market funds	$	48,704	$	—	$	—	$	48,704
Corporate bonds		6,254		—		(7)		6,247
Commercial paper		58,524		—		—		58,524
Government bonds		40,428		—		(125)		40,303
Total cash equivalents and available-for-sale securities	$	153,910	$	—	$	(132)	$	153,778
Classified as:
Cash equivalents							$	104,348
Available-for-sale securities - current								37,972
Available-for-sale securities - noncurrent								11,458
Total cash equivalents and available-for-sale securities							$	153,778

Summary of Accrued Expenses and Other Payables

Accrued expenses and other payables consisted of the following (in thousands):

	September 30,		December 31,
	2018		2017
Accrued clinical and research related expenses	$	7,649	$	6,437
Accrued employee related expenses		2,410		2,718
Accrued professional service fees		332		267
Other		105		124
Total accrued expenses and other payables	$	10,496	$	9,546